Table 1

Baseline characteristics of participants according to AT(N) category and CSVD burden

TotalNormal AD biomarkerNon-Alzheimer’s pathological changeAlzheimer’s pathological changeAD
V−V+V−V+V−V+V−V+
No205211215174415747
Age, years, mean (SD)74.1±8.673.4±5.270.2±6.578.1±7.880.0±5.577.3±8.280.9±3.371.5±8.682.0±6.1
Sex, female, n (%)129 (62.9)15 (71.4)5 (41.7)9 (60.0)14 (82.4)19 (43.2)14 (93.3)50 (67.6)3 (42.9)
Education, years, mean (SD)10.2±5.310.7±5.86.1±5.59.1±6.29.7±5.011.3±5.18.6±5.110.4±4.87.4±7.6
APOE ε4 carrier, n (%)89 (43.4)4 (19.0)4 (33.3)7 (46.7)3 (17.6)19 (43.2)5 (33.3)45 (60.8)2 (28.6)
Aβ PET dcCL, mean (SD)64.6±51.01.5±11.03.6±5.1−0.2±13.55.0±8.987.2±32.669.3±34.6103.3±29.793.9±17.6
Tau PET SUVR at Braak 34 ROI, mean (SD)2.1±0.71.5±0.11.5±0.11.7±0.41.8±0.31.6±0.41.7±0.12.8±0.72.3±0.3
HV volume (mm3), mean (SD)2424.1±582.32978.7±330.63180.8±428.72174.3±522.22240.2±443.32705.0±498.92221.2±442.32163.2±551.62014.0±333.1
WMH volume (mm3), mean (SD)21 923.3±23 648.27712.6±8265.354 915.8±21 601.919 365.8±13 529.858 084.3±17 544.312 297.6±11 221.255 207.6±19 884.57984.8±8299.248 370.1±1435.6
Baseline CDR-SOB, median (IQR)2.0 (0.5–3.5)0.5 (0.5–1.0)2.5 (0.5–3.5)1.75 (1.0–3.5)1.5 (0.5–6.0)0.5 (0.5–2.0)2.0 (1.0–2.5)2.5 (1.5–4.5)1.75 (1.5–4.0)
  • APOE, apolipoprotein E; Aβ, β-amyloid; CDR-SOB, clinical dementia rating sum of box scores; CSVD, cerebral small vessel disease; dcCL, direct comparison of Centiloid units; HV, hippocampal volume; n, number; PET, positron emission tomography; ROI, region of interest; SUVR, standard uptake value ratio; WMH, white matter hyperintensities.